AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06363695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual by Community Health Volunteers
Description: Community Health Volunteers support families with children up to age 5 around the physical health needs of family members, including delivering key health messages (e.g., importance of immunizations); treating minor injuries and illnesses; identifying/treating/referring common childhood illnesses (e.g., diarrhea, malaria); conducting home visits to evaluate the home environment and discuss improvements; and encouraging care at home and appropriate health seeking behaviors. These support services are not highly structured but rather tailored to the needs of each family.
Study NCT05490316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI353 (Orismilast)
Description: dose 1 or dose 2
Study NCT05490316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06089031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Function Test
Description: Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
Study NCT06090955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Study NCT06090955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Study NCT06090955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
Study NCT05401539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardboard VR
Description: Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
Study NCT05869786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)
Description: In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
Study NCT05795673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peer support program (intervention phase)
Description: Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints.
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
Study NCT05869786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: conventional rehabilitation program
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: CYP2C9 probe substrate
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: CYP2D6 probe substrate
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: CYP3A4 probe substrate
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: P-gp probe substrate
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: BCRP probe substrate
Study NCT04887194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor (PD-1) blocking antibody
Study NCT05339399 — intervention group
Intervention type: OTHER
Intervention: oxytocin augmentation
Description: Only observation of the outcome
Study NCT05869786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation program
Description: conventional rehabilitation program
Study NCT05869786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
Study NCT05272722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG,
Description: Holter monitoring
Study NCT05764252 — intervention group
Intervention type: DEVICE
Intervention: BioEP
Description: All patient's EEG will have the BioEP score conducted on it
Study NCT05679596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate
Description: Provided twice a day between meals.
Study NCT05679596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)
Description: Provided twice a day between meals.
Study NCT06269718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
Study NCT06269718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
Study NCT06269718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IOPI therapy
Description: tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
Study NCT04714983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNX-2440
Description: DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.
Study NCT05371938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volar locking plate
Description: Volar locking plate is the intervention
Study NCT05371938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external fixation
Description: surgery with external fixation
Study NCT06216197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FENT group
Description: Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
Study NCT06216197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DEX group
Description: The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
Study NCT04883567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The use of artificial intelligence system Cerebro
Description: The artificial intelligence system Cerebro would be used during OGD
Study NCT06165523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 340 mL plain tap water consumed immediately following glycogen depleting exercise
Study NCT06165523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored Kefir
Description: 320 mL kefir consumed immediately following glycogen depleting exercise
Study NCT06165523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored Milk
Description: 240 mL flavored milk consumed immediately following glycogen depleting exercise
Study NCT06552845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LGE-MRI Scan
Description: Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
Study NCT05679960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine PolypDx machine Versus Colonoscopy
Description: 1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups
Study NCT05047133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Study NCT05047133 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Study NCT06214442 — intervention group
Intervention type: OTHER
Intervention: Evaluations of the mechanical properties of the achilles tendon in different phases of the menstrual cycle
Description: Monitoring assessments to verify the effect of different phases of the menstrual cycle on the neuromechanical properties of the Achilles tendon.
Study NCT05186012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.
Study NCT05186012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Every 28 days as a cycle.
Study NCT05484427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Replacement of the regullar meeting with diabetologist by remote communication only
Study NCT05771805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with task oriented training
Description: VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
Study NCT05771805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task oriented training
Description: Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
Study NCT05201482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightPlus
Description: SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
Study NCT04525235 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: phenotyping cocktail
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Study NCT04525235 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: phenotyping cocktail
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Study NCT04525235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Study NCT04525235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampicin
Description: A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
Study NCT05843591 — intervention group
Intervention type: BEHAVIORAL
Intervention: aerobic exercise or Tai Chi Chuan interventions
Description: 8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
Study NCT05425303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exposure to risk for injury
Description: Athletes will be examined in the preseason stage and will be monitored during the competitive season.
Study NCT05188599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: İsokinetic assessment
Description: Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
Study NCT06302920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Lymphatic correction technique
Study NCT06107101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 100mg of mepolizumab every 4 weeks subcutaneously for 6 months
Study NCT05495958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin D eye drop
Description: 25 Microgram/cc or 1000 IU
Study NCT05495958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo eye drop
Description: The same-shape packed drop without vitamin D
Study NCT05276427 — intervention group
Intervention type: OTHER
Intervention: Non Clinical procedure
Description: Non clinical procedure- Informed consent completion and interview session
Study NCT06078891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Three intra-dermal vaccinations over a period of one year.
Study NCT05706870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GN-037
Description: GN-037
Study NCT05706870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 17-propionate
Description: Clobetasol 17-propionate
Study NCT05706870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06092255 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy for SVZ
Description: GBM patients who met the inclusion criteria received radiotherapy range and dose based on the EORTC outline principles. The ipsilateral and contralateral SVZ areas received 56Gy and 40Gy respectively, with a fractionated dose of 2Gy. Concurrent chemotherapy with temozolomide and six cycles of adjuvant temozolomide chemotherapy were performed at the same time as radiotherapy.
Study NCT06013410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: colonoscopy
Study NCT05392335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial stretch
Description: Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
Study NCT05392335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial stretch
Description: Myofascial stretch will be applied at hip adductors, hamstrings and calf muscles for 10 -15 repetitions on each muscle. 2-3 sessions will be performed in a week for 8 weeks.
Study NCT05392335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional massage along with myofacial stretch
Description: In this group during the first 20 minutes, ten minutes FM will be applied to each lower extremity of the subject. The muscle groups to which FM would be applied were hip adductors, hamstrings and calf muscles. During the remaining period traditional physiotherapy involving myofascial strecth will be given. 2-3 session will be performed in a week for 8 weeks.
Study NCT04929353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Systematic symptom assessment
Description: * Systematic symptom assessment~* Conventional symptom assessment
Study NCT05000424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clary Sage Massage Oil
Description: This massage oil contains clary sage oil. Five drops will be used daily.
Study NCT05000424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Massage Oil
Description: This massage oil consists entirely of plant based oils. Five drops will be used daily.
Study NCT06383689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seizure placebo pill
Description: patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
Study NCT06383689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-being placebo pill
Description: patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
Study NCT05098418 — intervention group
Intervention type: DRUG
Intervention: Poison
Description: standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
Study NCT05200728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1910-09
Description: Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Study NCT05200728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose.
Study NCT06219915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa 25 mg
Description: Participants will take one 25mg Carbidopa tablet 3 times a day for 10 days.
Study NCT06219915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa 25/100 mg
Description: Participants will take one 25/100mg carbidopa-levodopa tablet 3 times a day on days 4-6, then increase to 1.5 tablets 3 times a day on days 7-10.